

Inefficacy discontinuations

Dosing (mg)	Number of trials	Number (%) with outcome		Relative risk (95% CI)	NNH (95% CI)
		Sildenafil	Placebo		
25	3	8/312 (2.6)	18/426 (4.2)	0.64 (0.28 to 1.48)	
50	5	4/508 (0.8)	26/607 (4.3)	0.24 (0.09 to 0.61)	-28 (-19 to -58)
100	5	3/506 (0.6)	26/607 (4.3)	0.19 (0.07 to 0.54)	-27 (-18 to -51)
200	2	2/191 (1.0)	8/181 (4.4)	0.28 (0.07 to 1.16)	
Dose optimised	5	15/517 (2.9)	58/524 (11)	0.27 (0.16 to 0.45)	-12 (-9 to -20)